Hot Money Fuels China Biotech ‘Me-Different’ Ambitions
This article was originally published in PharmAsia News
Executive Summary
Adagene is the latest antibody firm to receive millions in financing, adding to a growing list of upcoming Chinese biotechs looking to differentiate in a largely unpenetrated yet competitive biologics market.